Good points of thought,
As a good investor, there should never be enough put into a stock like Cortex, especially at its stage in development to where a negative result would cause significant risk of financial stability to the investor; but then again there are always divergences with multiple facets.
Your statement that the rest of the world isn't watching Cortex with nearly the intensity we do, would serve you well.
The negative behind any trade possibility is zero.
What positives are known if good results are shown and what weak areas are solidified on good results have been off and on discussed
It is likely good results will have very good sp actions but no matter the possible positive action, the future growth would be significant with it.
If the decision for additional money into Cortex was being thought of, missing the initial uptick for future gains would seem most logical.
If good results are shown, I would not put much into the thought that quick financing would drive the sp down significantly.
If there are good results, Cortex will either make a quick deal with a company which will likely include a cash infusion or Cortex will make a financing which should be seen by the market as Cortex has data showing support and significant future income potential and are willing to grow the company and sp over any deal.
Although those thoughts of the market reactions may be too rational without regard to how things move in the market, the market may behave like a sleeping giant where the trial results may give it a nudge but the subsequent news may awaken it.
I am surprised there has not been any significant discussion on analgesia in the trials with respect to the analgesic receptor sites and MOA and review of ampakine receptor sites and pathways.
For a very simplified thought, what is the effect of taking a beta-blocker on pain relief from a cox-2 inhibitor. As far as opiates or barbiturates go, where do they exert their influence on reducing pain and in those areas are there any ampakine pathway connections which may negate their binding and action. Why would or how could an ampakine cause an effect at the opiate receptors with pain transmission or pain intensity or cause an effect with GABA receptors.
AI
